

### 16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Date	Vaccine Received			
							Dose 1	Date	Dose 2	
10011004	C4591001 1001 10011004	18-55	04MAY2020	1084	BNT162b1 (10 µg)	04MAY2020	BNT162b1 (10 µg)	26MAY2020	BNT162b1 (10 µg)	
10011005	C4591001 1001 10011005	18-55	06MAY2020	1093	Placebo	06MAY2020	Placebo	26MAY2020	Placebo	
10011006	C4591001 1001 10011006	18-55	06MAY2020	1090	BNT162b1 (10 µg)	06MAY2020	BNT162b1 (10 µg)	27MAY2020	BNT162b1 (10 µg)	
10011007	C4591001 1001 10011007	18-55	06MAY2020	1092	BNT162b1 (10 µg)	06MAY2020	BNT162b1 (10 µg)	28MAY2020	BNT162b1 (10 µg)	
10011008	C4591001 1001 10011008	18-55	06MAY2020	1094	BNT162b1 (10 µg)	06MAY2020	BNT162b1 (10 µg)	27MAY2020	BNT162b1 (10 µg)	
10011009	C4591001 1001 10011009	18-55	06MAY2020	1095	BNT162b1 (10 µg)	06MAY2020	BNT162b1 (10 µg)	27MAY2020	BNT162b1 (10 µg)	
10011011	C4591001 1001 10011011	18-55	11MAY2020	1220	BNT162b1 (30 µg)	11MAY2020	BNT162b1 (30 µg)	01JUN2020	BNT162b1 (30 µg)	
10011012	C4591001 1001 10011012	18-55	13MAY2020	1230	BNT162b1 (30 µg)	13MAY2020	BNT162b1 (30 µg)	03JUN2020	BNT162b1 (30 µg)	
10011015	C4591001 1001 10011015	18-55	11MAY2020	1219	BNT162b1 (30 µg)	11MAY2020	BNT162b1 (30 µg)	01JUN2020	BNT162b1 (30 µg)	
10011017	C4591001 1001 10011017	18-55	13MAY2020	1228	BNT162b1 (30 µg)	13MAY2020	BNT162b1 (30 µg)	03JUN2020	BNT162b1 (30 µg)	
10011019	C4591001 1001 10011019	18-55	13MAY2020	1229	BNT162b1 (30 µg)	13MAY2020	BNT162b1 (30 µg)	03JUN2020	BNT162b1 (30 µg)	
10011020	C4591001 1001 10011020	18-55	13MAY2020	1226	BNT162b1 (30 µg)	13MAY2020	BNT162b1 (30 µg)	03JUN2020	BNT162b1 (30 µg)	
10011024	C4591001 1001 10011024	18-55	13MAY2020	1225	BNT162b1 (30 µg)	13MAY2020	BNT162b1 (30 µg)	03JUN2020	BNT162b1 (30 µg)	
10011037	C4591001 1001 10011037	65-85	11JUN2020	1631	BNT162b1 (10 µg)	11JUN2020	BNT162b1 (10 µg)	30JUN2020	BNT162b1 (10 µg)	

### 16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10011039	C4591001 1001 10011039	65-85	09JUN2020	1624	BNT162b1 (10 µg)	09JUN2020	BNT162b1 (10 µg)	29JUN2020	BNT162b1 (10 µg)
10011040	C4591001 1001 10011040	65-85	11JUN2020	1635	BNT162b1 (10 µg)	11JUN2020	BNT162b1 (10 µg)	02JUL2020	BNT162b1 (10 µg)
10011041	C4591001 1001 10011041	65-85	11JUN2020	1632	BNT162b1 (10 µg)	11JUN2020	BNT162b1 (10 µg)	02JUL2020	BNT162b1 (10 µg)
10011042	C4591001 1001 10011042	65-85	11JUN2020	1634	Placebo	11JUN2020	Placebo	30JUN2020	Placebo
10011043	C4591001 1001 10011043	65-85	15JUN2020	2029	BNT162b1 (20 µg)	15JUN2020	BNT162b1 (20 µg)	08JUL2020	BNT162b1 (20 µg)
10011044	C4591001 1001 10011044	65-85	09JUN2020	1625	BNT162b1 (10 µg)	09JUN2020	BNT162b1 (10 µg)	29JUN2020	BNT162b1 (10 µg)
10011045	C4591001 1001 10011045	65-85	11JUN2020	1633	BNT162b1 (10 µg)	11JUN2020	BNT162b1 (10 µg)	02JUL2020	BNT162b1 (10 µg)
10011046	C4591001 1001 10011046	65-85	18JUN2020	1767	BNT162b1 (30 µg)	18JUN2020	BNT162b1 (30 µg)	09JUL2020	BNT162b1 (30 µg)
10011048	C4591001 1001 10011048	65-85	16JUN2020	1759	BNT162b1 (30 µg)	16JUN2020	BNT162b1 (30 µg)	08JUL2020	BNT162b1 (30 µg)
10011049	C4591001 1001 10011049	65-85	15JUN2020	2030	BNT162b1 (20 µg)	15JUN2020	BNT162b1 (20 µg)	06JUL2020	BNT162b1 (20 µg)
10011050	C4591001 1001 10011050	65-85	17JUN2020	2031	BNT162b1 (20 µg)	17JUN2020	BNT162b1 (20 µg)	07JUL2020	BNT162b1 (20 µg)
10011052	C4591001 1001 10011052	65-85	17JUN2020	2037	BNT162b1 (20 µg)	17JUN2020	BNT162b1 (20 µg)	08JUL2020	BNT162b1 (20 µg)
10011053	C4591001 1001 10011053	65-85	16JUN2020	1760	Placebo	16JUN2020	Placebo	09JUL2020	Placebo
10011055	C4591001 1001 10011055	65-85	17JUN2020	2039	BNT162b1 (20 µg)	17JUN2020	BNT162b1 (20 µg)	08JUL2020	BNT162b1 (20 µg)

### 16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10011057	C4591001 1001 10011057	65-85	17JUN2020	2038	Placebo	17JUN2020	Placebo	08JUL2020	Placebo
10011058	C4591001 1001 10011058	65-85	18JUN2020	1768	BNT162b1 (30 µg)	18JUN2020	BNT162b1 (30 µg)	09JUL2020	BNT162b1 (30 µg)
10011059	C4591001 1001 10011059	65-85	17JUN2020	2040	BNT162b1 (20 µg)	17JUN2020	BNT162b1 (20 µg)	08JUL2020	BNT162b1 (20 µg)
10011061	C4591001 1001 10011061	65-85	18JUN2020	1765	BNT162b1 (30 µg)	18JUN2020	BNT162b1 (30 µg)	09JUL2020	BNT162b1 (30 µg)
10011063	C4591001 1001 10011063	65-85	18JUN2020	1769	BNT162b1 (30 µg)	18JUN2020	BNT162b1 (30 µg)	07JUL2020	BNT162b1 (30 µg)
10011064	C4591001 1001 10011064	65-85	18JUN2020	1770	Placebo	18JUN2020	Placebo	07JUL2020	Placebo
10011066	C4591001 1001 10011066	18-55	29JUN2020	1489	Placebo	29JUN2020	Placebo	20JUL2020	Placebo
10011067	C4591001 1001 10011067	18-55	01JUL2020	1499	BNT162b1 (20 µg)	01JUL2020	BNT162b1 (20 µg)	22JUL2020	BNT162b1 (20 µg)
10011068	C4591001 1001 10011068	18-55	29JUN2020	1490	BNT162b1 (20 µg)	29JUN2020	BNT162b1 (20 µg)	20JUL2020	BNT162b1 (20 µg)
10011069	C4591001 1001 10011069	18-55	01JUL2020	1496	Placebo	01JUL2020	Placebo	22JUL2020	Placebo
10011070	C4591001 1001 10011070	18-55	01JUL2020	1500	BNT162b1 (20 µg)	01JUL2020	BNT162b1 (20 µg)	22JUL2020	BNT162b1 (20 µg)
10011071	C4591001 1001 10011071	18-55	01JUL2020	1497	BNT162b1 (20 µg)	01JUL2020	BNT162b1 (20 µg)	22JUL2020	BNT162b1 (20 µg)
10011076	C4591001 1001 10011076	18-55	01JUL2020	1498	BNT162b1 (20 µg)	01JUL2020	BNT162b1 (20 µg)	21JUL2020	BNT162b1 (20 µg)
10021003	C4591001 1002 10021003	18-55	04MAY2020	1081	BNT162b1 (10 µg)	04MAY2020	BNT162b1 (10 µg)	26MAY2020	BNT162b1 (10 µg)

### 16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Date	Vaccine Received			
							Dose 1	Date	Dose 2	
10021004	C4591001 1002 10021004	18-55	04MAY2020	1082	BNT162b1 (10 µg)	04MAY2020	BNT162b1 (10 µg)	26MAY2020	BNT162b1 (10 µg)	
10021005	C4591001 1002 10021005	18-55	04MAY2020	1083	Placebo	04MAY2020	Placebo	26MAY2020	Placebo	
10021006	C4591001 1002 10021006	18-55	11MAY2020	1218	BNT162b1 (30 µg)	11MAY2020	BNT162b1 (30 µg)	02JUN2020	BNT162b1 (30 µg)	
10021007	C4591001 1002 10021007	18-55	06MAY2020	1089	BNT162b1 (10 µg)	06MAY2020	BNT162b1 (10 µg)	26MAY2020	BNT162b1 (10 µg)	
10021008	C4591001 1002 10021008	18-55	06MAY2020	1088	Placebo	06MAY2020	Placebo	26MAY2020	Placebo	
10021009	C4591001 1002 10021009	18-55	06MAY2020	1091	BNT162b1 (10 µg)	06MAY2020	BNT162b1 (10 µg)	26MAY2020	BNT162b1 (10 µg)	
10021011	C4591001 1002 10021011	18-55	06MAY2020	1086	BNT162b1 (10 µg)	06MAY2020	BNT162b1 (10 µg)	26MAY2020	BNT162b1 (10 µg)	
10021012	C4591001 1002 10021012	18-55	05MAY2020	1085	BNT162b1 (10 µg)	05MAY2020	BNT162b1 (10 µg)	26MAY2020	BNT162b1 (10 µg)	
10021013	C4591001 1002 10021013	18-55	06MAY2020	1087	BNT162b1 (10 µg)	06MAY2020	BNT162b1 (10 µg)	26MAY2020	BNT162b1 (10 µg)	
10021014	C4591001 1002 10021014	18-55	13MAY2020	1224	BNT162b1 (30 µg)	13MAY2020	BNT162b1 (30 µg)	02JUN2020	BNT162b1 (30 µg)	
10021015	C4591001 1002 10021015	18-55	11MAY2020	1216	BNT162b1 (30 µg)	11MAY2020	BNT162b1 (30 µg)	02JUN2020	BNT162b1 (30 µg)	
10021017	C4591001 1002 10021017	18-55	13MAY2020	1221	BNT162b1 (30 µg)	13MAY2020	BNT162b1 (30 µg)	02JUN2020	BNT162b1 (30 µg)	
10021018	C4591001 1002 10021018	18-55	11MAY2020	1217	Placebo	11MAY2020	Placebo	02JUN2020	Placebo	
10021020	C4591001 1002 10021020	18-55	13MAY2020	1222	BNT162b1 (30 µg)	13MAY2020	BNT162b1 (30 µg)	02JUN2020	BNT162b1 (30 µg)	

### 16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Date	Vaccine Received			
							Dose 1	Date	Dose 2	
10021021	C4591001 1002 10021021	18-55	13MAY2020	1223	Placebo	13MAY2020	Placebo	02JUN2020	Placebo	
10021022	C4591001 1002 10021022	18-55	13MAY2020	1227	Placebo	13MAY2020	Placebo	02JUN2020	Placebo	
10021042	C4591001 1002 10021042	65-85	09JUN2020	1623	Placebo	09JUN2020	Placebo	30JUN2020	Placebo	
10021043	C4591001 1002 10021043	65-85	09JUN2020	1621	BNT162b1 (10 µg)	09JUN2020	BNT162b1 (10 µg)	30JUN2020	BNT162b1 (10 µg)	
10021044	C4591001 1002 10021044	65-85	09JUN2020	1622	BNT162b1 (10 µg)	09JUN2020	BNT162b1 (10 µg)	30JUN2020	BNT162b1 (10 µg)	
10021045	C4591001 1002 10021045	65-85	11JUN2020	1629	BNT162b1 (10 µg)	11JUN2020	BNT162b1 (10 µg)	30JUN2020	BNT162b1 (10 µg)	
10021047	C4591001 1002 10021047	65-85	11JUN2020	1626	Placebo	11JUN2020	Placebo	30JUN2020	Placebo	
10021049	C4591001 1002 10021049	65-85	11JUN2020	1630	BNT162b1 (10 µg)	11JUN2020	BNT162b1 (10 µg)	30JUN2020	BNT162b1 (10 µg)	
10021050	C4591001 1002 10021050	65-85	15JUN2020	2026	Placebo	15JUN2020	Placebo	07JUL2020	Placebo	
10021052	C4591001 1002 10021052	65-85	11JUN2020	1628	BNT162b1 (10 µg)	11JUN2020	BNT162b1 (10 µg)	30JUN2020	BNT162b1 (10 µg)	
10021053	C4591001 1002 10021053	65-85	11JUN2020	1627	BNT162b1 (10 µg)	11JUN2020	BNT162b1 (10 µg)	30JUN2020	BNT162b1 (10 µg)	
10021054	C4591001 1002 10021054	65-85	15JUN2020	2028	BNT162b1 (20 µg)	15JUN2020	BNT162b1 (20 µg)	07JUL2020	BNT162b1 (20 µg)	
10021059	C4591001 1002 10021059	65-85	15JUN2020	1757	BNT162b1 (30 µg)	15JUN2020	BNT162b1 (30 µg)	07JUL2020	BNT162b1 (30 µg)	
10021060	C4591001 1002 10021060	65-85	15JUN2020	2027	BNT162b1 (20 µg)	15JUN2020	BNT162b1 (20 µg)	07JUL2020	BNT162b1 (20 µg)	

### 16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Date	Vaccine Received			
							Dose 1	Date	Dose 2	
10021062	C4591001 1002 10021062	65-85	15JUN2020	1756	BNT162b1 (30 µg)	15JUN2020	BNT162b1 (30 µg)	07JUL2020	BNT162b1 (30 µg)	
10021063	C4591001 1002 10021063	65-85	15JUN2020	1758	BNT162b1 (30 µg)	15JUN2020	BNT162b1 (30 µg)	07JUL2020	BNT162b1 (30 µg)	
10021064	C4591001 1002 10021064	65-85	17JUN2020	2034	BNT162b1 (20 µg)	17JUN2020	BNT162b1 (20 µg)	08JUL2020	BNT162b1 (20 µg)	
10021067	C4591001 1002 10021067	65-85	17JUN2020	2032	BNT162b1 (20 µg)	17JUN2020	BNT162b1 (20 µg)	08JUL2020	BNT162b1 (20 µg)	
10021068	C4591001 1002 10021068	65-85	17JUN2020	2035	BNT162b1 (20 µg)	17JUN2020	BNT162b1 (20 µg)	08JUL2020	BNT162b1 (20 µg)	
10021069	C4591001 1002 10021069	65-85	18JUN2020	1764	BNT162b1 (30 µg)	18JUN2020	BNT162b1 (30 µg)	08JUL2020	BNT162b1 (30 µg)	
10021071	C4591001 1002 10021071	65-85	17JUN2020	2036	BNT162b1 (20 µg)	17JUN2020	BNT162b1 (20 µg)	08JUL2020	BNT162b1 (20 µg)	
10021072	C4591001 1002 10021072	65-85	18JUN2020	1761	Placebo	18JUN2020	Placebo	08JUL2020	Placebo	
10021073	C4591001 1002 10021073	65-85	17JUN2020	2033	Placebo	17JUN2020	Placebo	08JUL2020	Placebo	
10021074	C4591001 1002 10021074	65-85	18JUN2020	1762	BNT162b1 (30 µg)	18JUN2020	BNT162b1 (30 µg)	08JUL2020	BNT162b1 (30 µg)	
10021075	C4591001 1002 10021075	65-85	18JUN2020	1766	BNT162b1 (30 µg)	18JUN2020	BNT162b1 (30 µg)	08JUL2020	BNT162b1 (30 µg)	
10021077	C4591001 1002 10021077	65-85	18JUN2020	1763	BNT162b1 (30 µg)	18JUN2020	BNT162b1 (30 µg)	08JUL2020	BNT162b1 (30 µg)	
10021079	C4591001 1002 10021079	18-55	29JUN2020	1487	BNT162b1 (20 µg)	29JUN2020	BNT162b1 (20 µg)	21JUL2020	BNT162b1 (20 µg)	
10021080	C4591001 1002 10021080	18-55	01JUL2020	1491	BNT162b1 (20 µg)	01JUL2020	BNT162b1 (20 µg)	21JUL2020	BNT162b1 (20 µg)	

### 16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10021081	C4591001 1002 10021081	18-55	01JUL2020	1492	BNT162b1 (20 µg)	01JUL2020	BNT162b1 (20 µg)	21JUL2020	BNT162b1 (20 µg)
10021082	C4591001 1002 10021082	18-55	01JUL2020	1494	BNT162b1 (20 µg)	01JUL2020	BNT162b1 (20 µg)	21JUL2020	BNT162b1 (20 µg)
10021083	C4591001 1002 10021083	18-55	01JUL2020	1495	Placebo	01JUL2020	Placebo	21JUL2020	Placebo
10021084	C4591001 1002 10021084	18-55	29JUN2020	1488	BNT162b1 (20 µg)	29JUN2020	BNT162b1 (20 µg)	21JUL2020	BNT162b1 (20 µg)
10021085	C4591001 1002 10021085	18-55	29JUN2020	1486	BNT162b1 (20 µg)	29JUN2020	BNT162b1 (20 µg)	21JUL2020	BNT162b1 (20 µg)
10021087	C4591001 1002 10021087	18-55	01JUL2020	1493	BNT162b1 (20 µg)	01JUL2020	BNT162b1 (20 µg)	21JUL2020	BNT162b1 (20 µg)
10031016	C4591001 1003 10031016	18-55	09JUN2020	2164	Placebo	09JUN2020	Placebo	30JUN2020	Placebo
10031017	C4591001 1003 10031017	18-55	11JUN2020	2172	Placebo	11JUN2020	Placebo	02JUL2020	Placebo
10031018	C4591001 1003 10031018	18-55	09JUN2020	2163	BNT162b2 (10 µg)	09JUN2020	BNT162b2 (10 µg)	30JUN2020	BNT162b2 (10 µg)
10031019	C4591001 1003 10031019	18-55	11JUN2020	2170	BNT162b2 (10 µg)	11JUN2020	BNT162b2 (10 µg)	02JUL2020	BNT162b2 (10 µg)
10031020	C4591001 1003 10031020	18-55	11JUN2020	2174	BNT162b2 (10 µg)	11JUN2020	BNT162b2 (10 µg)	02JUL2020	BNT162b2 (10 µg)
10031021	C4591001 1003 10031021	18-55	09JUN2020	2165	BNT162b2 (10 µg)	09JUN2020	BNT162b2 (10 µg)	30JUN2020	BNT162b2 (10 µg)
10031022	C4591001 1003 10031022	18-55	11JUN2020	2171	BNT162b2 (10 µg)	11JUN2020	BNT162b2 (10 µg)	02JUL2020	BNT162b2 (10 µg)
10031024	C4591001 1003 10031024	18-55	11JUN2020	2173	BNT162b2 (10 µg)	11JUN2020	BNT162b2 (10 µg)	02JUL2020	BNT162b2 (10 µg)

### 16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10031026	C4591001 1003 10031026	18-55	17JUN2020	2573	BNT162b2 (20 µg)	17JUN2020	BNT162b2 (20 µg)	08JUL2020	BNT162b2 (20 µg)
10031027	C4591001 1003 10031027	18-55	15JUN2020	2567	BNT162b2 (20 µg)	15JUN2020	BNT162b2 (20 µg)	06JUL2020	BNT162b2 (20 µg)
10031028	C4591001 1003 10031028	18-55	15JUN2020	2566	BNT162b2 (20 µg)	15JUN2020	BNT162b2 (20 µg)	06JUL2020	BNT162b2 (20 µg)
10031029	C4591001 1003 10031029	18-55	15JUN2020	2568	Placebo	15JUN2020	Placebo	06JUL2020	Placebo
10031030	C4591001 1003 10031030	18-55	17JUN2020	2575	BNT162b2 (20 µg)	17JUN2020	BNT162b2 (20 µg)	08JUL2020	BNT162b2 (20 µg)
10031031	C4591001 1003 10031031	65-85	15JUN2020	3109	BNT162b2 (20 µg)	15JUN2020	BNT162b2 (20 µg)	06JUL2020	BNT162b2 (20 µg)
10031032	C4591001 1003 10031032	18-55	17JUN2020	2572	BNT162b2 (20 µg)	17JUN2020	BNT162b2 (20 µg)	08JUL2020	BNT162b2 (20 µg)
10031034	C4591001 1003 10031034	18-55	17JUN2020	2571	Placebo	17JUN2020	Placebo	08JUL2020	Placebo
10031035	C4591001 1003 10031035	65-85	15JUN2020	3108	BNT162b2 (20 µg)	15JUN2020	BNT162b2 (20 µg)	06JUL2020	BNT162b2 (20 µg)
10031036	C4591001 1003 10031036	65-85	15JUN2020	3110	Placebo	15JUN2020	Placebo	06JUL2020	Placebo
10031037	C4591001 1003 10031037	65-85	16JUN2020	2840	BNT162b2 (30 µg)	16JUN2020	BNT162b2 (30 µg)	07JUL2020	BNT162b2 (30 µg)
10031038	C4591001 1003 10031038	18-55	17JUN2020	2574	BNT162b2 (20 µg)	17JUN2020	BNT162b2 (20 µg)	08JUL2020	BNT162b2 (20 µg)
10031043	C4591001 1003 10031043	65-85	16JUN2020	2838	Placebo	16JUN2020	Placebo	07JUL2020	Placebo
10031046	C4591001 1003 10031046	65-85	18JUN2020	2847	Placebo	18JUN2020	Placebo	09JUL2020	Placebo



### 16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Date	Vaccine Received			
							Dose 1	Date	Dose 2	
10031047	C4591001 1003 10031047	65-85	16JUN2020	2839	BNT162b2 (30 µg)	16JUN2020	BNT162b2 (30 µg)	07JUL2020	BNT162b2 (30 µg)	
10031050	C4591001 1003 10031050	18-55	22JUN2020	2297	Placebo	22JUN2020	Placebo	13JUL2020	Placebo	
10031051	C4591001 1003 10031051	65-85	18JUN2020	2848	BNT162b2 (30 µg)	18JUN2020	BNT162b2 (30 µg)	09JUL2020	BNT162b2 (30 µg)	
10031053	C4591001 1003 10031053	65-85	17JUN2020	3111	BNT162b2 (20 µg)	17JUN2020	BNT162b2 (20 µg)	08JUL2020	BNT162b2 (20 µg)	
10031054	C4591001 1003 10031054	65-85	17JUN2020	3115	BNT162b2 (20 µg)	17JUN2020	BNT162b2 (20 µg)	08JUL2020	BNT162b2 (20 µg)	
10031055	C4591001 1003 10031055	65-85	17JUN2020	3112	BNT162b2 (20 µg)	17JUN2020	BNT162b2 (20 µg)	06JUL2020	BNT162b2 (20 µg)	
10031056	C4591001 1003 10031056	65-85	18JUN2020	2844	Placebo	18JUN2020	Placebo	09JUL2020	Placebo	
10031057	C4591001 1003 10031057	18-55	24JUN2020	2301	BNT162b2 (30 µg)	24JUN2020	BNT162b2 (30 µg)	15JUL2020	BNT162b2 (30 µg)	
10031058	C4591001 1003 10031058	65-85	18JUN2020	2846	BNT162b2 (30 µg)	18JUN2020	BNT162b2 (30 µg)	09JUL2020	BNT162b2 (30 µg)	
10031059	C4591001 1003 10031059	18-55	24JUN2020	2305	BNT162b2 (30 µg)	24JUN2020	BNT162b2 (30 µg)	15JUL2020	BNT162b2 (30 µg)	
10031061	C4591001 1003 10031061	18-55	22JUN2020	2298	BNT162b2 (30 µg)	22JUN2020	BNT162b2 (30 µg)	13JUL2020	BNT162b2 (30 µg)	
10031063	C4591001 1003 10031063	65-85	17JUN2020	3113	BNT162b2 (20 µg)	17JUN2020	BNT162b2 (20 µg)	08JUL2020	BNT162b2 (20 µg)	
10031065	C4591001 1003 10031065	18-55	24JUN2020	2303	BNT162b2 (30 µg)	24JUN2020	BNT162b2 (30 µg)	15JUL2020	BNT162b2 (30 µg)	
10031066	C4591001 1003 10031066	18-55	22JUN2020	2296	BNT162b2 (30 µg)	22JUN2020	BNT162b2 (30 µg)	13JUL2020	BNT162b2 (30 µg)	

### 16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10031067	C4591001 1003 10031067	65-85	17JUN2020	3114	Placebo	17JUN2020	Placebo	08JUL2020	Placebo
10031069	C4591001 1003 10031069	65-85	18JUN2020	2845	BNT162b2 (30 µg)	18JUN2020	BNT162b2 (30 µg)	09JUL2020	BNT162b2 (30 µg)
10031070	C4591001 1003 10031070	18-55	24JUN2020	2304	Placebo	24JUN2020	Placebo	15JUL2020	Placebo
10031072	C4591001 1003 10031072	18-55	24JUN2020	2302	BNT162b2 (30 µg)	24JUN2020	BNT162b2 (30 µg)	16JUL2020	BNT162b2 (30 µg)
10031076	C4591001 1003 10031076	65-85	29JUN2020	2702	BNT162b2 (10 µg)	29JUN2020	BNT162b2 (10 µg)	20JUL2020	BNT162b2 (10 µg)
10031077	C4591001 1003 10031077	65-85	01JUL2020	2711	BNT162b2 (10 µg)	01JUL2020	BNT162b2 (10 µg)	22JUL2020	BNT162b2 (10 µg)
10031078	C4591001 1003 10031078	65-85	01JUL2020	2712	BNT162b2 (10 µg)	01JUL2020	BNT162b2 (10 µg)	22JUL2020	BNT162b2 (10 µg)
10031079	C4591001 1003 10031079	65-85	01JUL2020	2715	BNT162b2 (10 µg)	01JUL2020	BNT162b2 (10 µg)	22JUL2020	BNT162b2 (10 µg)
10031080	C4591001 1003 10031080	65-85	29JUN2020	2703	BNT162b2 (10 µg)	29JUN2020	BNT162b2 (10 µg)	20JUL2020	BNT162b2 (10 µg)
10031083	C4591001 1003 10031083	65-85	01JUL2020	2714	Placebo	01JUL2020	Placebo	22JUL2020	Placebo
10031087	C4591001 1003 10031087	65-85	01JUL2020	2713	BNT162b2 (10 µg)	01JUL2020	BNT162b2 (10 µg)	22JUL2020	BNT162b2 (10 µg)
10071014	C4591001 1007 10071014	18-55	11JUN2020	2175	BNT162b2 (10 µg)	11JUN2020	BNT162b2 (10 µg)	01JUL2020	BNT162b2 (10 µg)
10071015	C4591001 1007 10071015	18-55	08JUN2020	2161	BNT162b2 (10 µg)	08JUN2020	BNT162b2 (10 µg)	29JUN2020	BNT162b2 (10 µg)
10071016	C4591001 1007 10071016	18-55	10JUN2020	2166	BNT162b2 (10 µg)	10JUN2020	BNT162b2 (10 µg)	01JUL2020	BNT162b2 (10 µg)

### 16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Date	Vaccine Received			
							Dose 1	Date	Dose 2	
10071017	C4591001 1007 10071017	18-55	15JUN2020	2569	BNT162b2 (20 µg)	15JUN2020	BNT162b2 (20 µg)	06JUL2020	BNT162b2 (20 µg)	
10071019	C4591001 1007 10071019	18-55	08JUN2020	2162	BNT162b2 (10 µg)	08JUN2020	BNT162b2 (10 µg)	29JUN2020	BNT162b2 (10 µg)	
10071020	C4591001 1007 10071020	18-55	10JUN2020	2167	Placebo	10JUN2020	Placebo	01JUL2020	Placebo	
10071021	C4591001 1007 10071021	18-55	10JUN2020	2168	BNT162b2 (10 µg)	10JUN2020	BNT162b2 (10 µg)	01JUL2020	BNT162b2 (10 µg)	
10071022	C4591001 1007 10071022	18-55	10JUN2020	2169	BNT162b2 (10 µg)	10JUN2020	BNT162b2 (10 µg)	01JUL2020	BNT162b2 (10 µg)	
10071023	C4591001 1007 10071023	18-55	17JUN2020	2577	BNT162b2 (20 µg)	17JUN2020	BNT162b2 (20 µg)	08JUL2020	BNT162b2 (20 µg)	
10071025	C4591001 1007 10071025	18-55	17JUN2020	2580	Placebo	17JUN2020	Placebo	08JUL2020	Placebo	
10071026	C4591001 1007 10071026	18-55	15JUN2020	2570	BNT162b2 (20 µg)	15JUN2020	BNT162b2 (20 µg)	06JUL2020	BNT162b2 (20 µg)	
10071027	C4591001 1007 10071027	18-55	17JUN2020	2576	BNT162b2 (20 µg)	17JUN2020	BNT162b2 (20 µg)	08JUL2020	BNT162b2 (20 µg)	
10071029	C4591001 1007 10071029	18-55	17JUN2020	2578	BNT162b2 (20 µg)	17JUN2020	BNT162b2 (20 µg)	08JUL2020	BNT162b2 (20 µg)	
10071031	C4591001 1007 10071031	65-85	17JUN2020	3117	BNT162b2 (20 µg)	17JUN2020	BNT162b2 (20 µg)	08JUL2020	BNT162b2 (20 µg)	
10071032	C4591001 1007 10071032	65-85	15JUN2020	3106	BNT162b2 (20 µg)	15JUN2020	BNT162b2 (20 µg)	06JUL2020	BNT162b2 (20 µg)	
10071034	C4591001 1007 10071034	65-85	15JUN2020	2836	BNT162b2 (30 µg)	15JUN2020	BNT162b2 (30 µg)	06JUL2020	BNT162b2 (30 µg)	
10071035	C4591001 1007 10071035	65-85	15JUN2020	3107	BNT162b2 (20 µg)	15JUN2020	BNT162b2 (20 µg)	06JUL2020	BNT162b2 (20 µg)	

### 16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10071037	C4591001 1007 10071037	65-85	15JUN2020	2837	BNT162b2 (30 µg)	15JUN2020	BNT162b2 (30 µg)	06JUL2020	BNT162b2 (30 µg)
10071038	C4591001 1007 10071038	65-85	17JUN2020	3120	BNT162b2 (20 µg)	17JUN2020	BNT162b2 (20 µg)	08JUL2020	BNT162b2 (20 µg)
10071039	C4591001 1007 10071039	65-85	17JUN2020	3118	BNT162b2 (20 µg)	17JUN2020	BNT162b2 (20 µg)	08JUL2020	BNT162b2 (20 µg)
10071040	C4591001 1007 10071040	18-55	17JUN2020	2579	BNT162b2 (20 µg)	17JUN2020	BNT162b2 (20 µg)	08JUL2020	BNT162b2 (20 µg)
10071042	C4591001 1007 10071042	65-85	17JUN2020	3119	Placebo	17JUN2020	Placebo	08JUL2020	Placebo
10071043	C4591001 1007 10071043	65-85	18JUN2020	2843	BNT162b2 (30 µg)	18JUN2020	BNT162b2 (30 µg)	09JUL2020	BNT162b2 (30 µg)
10071044	C4591001 1007 10071044	65-85	18JUN2020	2841	BNT162b2 (30 µg)	18JUN2020	BNT162b2 (30 µg)	09JUL2020	BNT162b2 (30 µg)
10071045	C4591001 1007 10071045	65-85	18JUN2020	2842	BNT162b2 (30 µg)	18JUN2020	BNT162b2 (30 µg)	09JUL2020	BNT162b2 (30 µg)
10071046	C4591001 1007 10071046	18-55	22JUN2020	2299	BNT162b2 (30 µg)	22JUN2020	BNT162b2 (30 µg)	15JUL2020	BNT162b2 (30 µg)
10071049	C4591001 1007 10071049	65-85	18JUN2020	2849	BNT162b2 (30 µg)	18JUN2020	BNT162b2 (30 µg)	09JUL2020	BNT162b2 (30 µg)
10071050	C4591001 1007 10071050	18-55	22JUN2020	2300	BNT162b2 (30 µg)	22JUN2020	BNT162b2 (30 µg)	13JUL2020	BNT162b2 (30 µg)
10071051	C4591001 1007 10071051	65-85	29JUN2020	2701	BNT162b2 (10 µg)	29JUN2020	BNT162b2 (10 µg)	20JUL2020	BNT162b2 (10 µg)
10071052	C4591001 1007 10071052	65-85	17JUN2020	3116	BNT162b2 (20 µg)	17JUN2020	BNT162b2 (20 µg)	08JUL2020	BNT162b2 (20 µg)
10071053	C4591001 1007 10071053	65-85	18JUN2020	2850	BNT162b2 (30 µg)	18JUN2020	BNT162b2 (30 µg)	09JUL2020	BNT162b2 (30 µg)

### 16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Date	Vaccine Received		
							Dose 1	Date	Dose 2
10071056	C4591001 1007 10071056	65-85	29JUN2020	2704	Placebo	29JUN2020	Placebo	20JUL2020	Placebo
10071057	C4591001 1007 10071057	65-85	30JUN2020	2706	BNT162b2 (10 µg)	30JUN2020	BNT162b2 (10 µg)	22JUL2020	BNT162b2 (10 µg)
10071058	C4591001 1007 10071058	18-55	24JUN2020	2309	BNT162b2 (30 µg)	24JUN2020	BNT162b2 (30 µg)	15JUL2020	BNT162b2 (30 µg)
10071063	C4591001 1007 10071063	18-55	24JUN2020	2306	BNT162b2 (30 µg)	24JUN2020	BNT162b2 (30 µg)	15JUL2020	BNT162b2 (30 µg)
10071064	C4591001 1007 10071064	18-55	24JUN2020	2307	BNT162b2 (30 µg)	24JUN2020	BNT162b2 (30 µg)	15JUL2020	BNT162b2 (30 µg)
10071065	C4591001 1007 10071065	18-55	24JUN2020	2308	Placebo	24JUN2020	Placebo	15JUL2020	Placebo
10071066	C4591001 1007 10071066	18-55	24JUN2020	2310	BNT162b2 (30 µg)	24JUN2020	BNT162b2 (30 µg)	15JUL2020	BNT162b2 (30 µg)
10071071	C4591001 1007 10071071	65-85	29JUN2020	2705	BNT162b2 (10 µg)	29JUN2020	BNT162b2 (10 µg)	20JUL2020	BNT162b2 (10 µg)
10071073	C4591001 1007 10071073	65-85	30JUN2020	2707	BNT162b2 (10 µg)	30JUN2020	BNT162b2 (10 µg)	22JUL2020	BNT162b2 (10 µg)
10071074	C4591001 1007 10071074	65-85	30JUN2020	2708	BNT162b2 (10 µg)	30JUN2020	BNT162b2 (10 µg)	20JUL2020	BNT162b2 (10 µg)
10071075	C4591001 1007 10071075	65-85	30JUN2020	2710	Placebo	30JUN2020	Placebo	22JUL2020	Placebo
10071077	C4591001 1007 10071077	65-85	30JUN2020	2709	BNT162b2 (10 µg)	30JUN2020	BNT162b2 (10 µg)	22JUL2020	BNT162b2 (10 µg)

a. Subject Study Identifier = the subject number is the current study 4-digit site number followed by unique 4-digit subject identifier.

PFIZER CONFIDENTIAL SDTM Creation: 28AUG2020 (16:27) Source Data: adsl Table Generation: 02SEP2020 (17:24)

(Cutoff Date: 24AUG2020, Snapshot Date: 28AUG2020) Output File: (CDISC)/C4591001\_IA\_P1/adsl\_1003\_p1

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1 – BNT162b1 (100 µg)**

Study Subject Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received	
						Date	Dose 1
10011013	C4591001 1001 10011013	18-55	18MAY2020	1355	Placebo	18MAY2020	Placebo
10011021	C4591001 1001 10011021	18-55	20MAY2020	1356	Placebo	20MAY2020	Placebo
10011026	C4591001 1001 10011026	18-55	18MAY2020	1354	BNT162b1 (100 µg)	18MAY2020	BNT162b1 (100 µg)
10011028	C4591001 1001 10011028	18-55	20MAY2020	1359	BNT162b1 (100 µg)	20MAY2020	BNT162b1 (100 µg)
10011030	C4591001 1001 10011030	18-55	20MAY2020	1357	BNT162b1 (100 µg)	20MAY2020	BNT162b1 (100 µg)
10011032	C4591001 1001 10011032	18-55	20MAY2020	1360	BNT162b1 (100 µg)	20MAY2020	BNT162b1 (100 µg)
10011034	C4591001 1001 10011034	18-55	20MAY2020	1358	BNT162b1 (100 µg)	20MAY2020	BNT162b1 (100 µg)
10021023	C4591001 1002 10021023	18-55	18MAY2020	1352	BNT162b1 (100 µg)	18MAY2020	BNT162b1 (100 µg)
10021024	C4591001 1002 10021024	18-55	18MAY2020	1353	BNT162b1 (100 µg)	18MAY2020	BNT162b1 (100 µg)
10021027	C4591001 1002 10021027	18-55	18MAY2020	1351	BNT162b1 (100 µg)	18MAY2020	BNT162b1 (100 µg)
10021034	C4591001 1002 10021034	18-55	21MAY2020	1363	BNT162b1 (100 µg)	21MAY2020	BNT162b1 (100 µg)

### 16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1 – BNT162b1 (100 µg)

Study Subject Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received	
						Date	Dose 1
10021035	C4591001 1002 10021035	18-55	21MAY2020	1361	BNT162b1 (100 µg)	21MAY2020	BNT162b1 (100 µg)
10021036	C4591001 1002 10021036	18-55	21MAY2020	1364	BNT162b1 (100 µg)	21MAY2020	BNT162b1 (100 µg)
10021038	C4591001 1002 10021038	18-55	21MAY2020	1365	BNT162b1 (100 µg)	21MAY2020	BNT162b1 (100 µg)
10021041	C4591001 1002 10021041	18-55	21MAY2020	1362	Placebo	21MAY2020	Placebo

a. Subject Study Identifier = the subject number is the current study 4-digit site number followed by unique 4-digit subject identifier.  
 PFIZER CONFIDENTIAL SDTM Creation: 28AUG2020 (16:27) Source Data: adsl Table Generation: 19SEP2020 (10:20)  
 (Cutoff Date: 24AUG2020, Snapshot Date: 28AUG2020) Output File: ./nda3/C4591001 IA P1 100/adsl 1003 100 p1